Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 07/22 10:00:00 pm
165.67 USD   +0.90%
07/22 AMGEN : Announces Webcast Of 2016 Second Quarter Financial Results
07/22 AMGEN : Announces 2016 Third Quarter Dividend
07/22 AMGEN : And UCB Submit Biologics License Application For Romosozumab..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
07/22 AMGEN : Announces Webcast Of 2016 Second Quarter Financial Results
07/22 AMGEN : Announces 2016 Third Quarter Dividend
07/22 AMGEN : Owen Smith to pledge equal representation of women in Labour
07/22 AMGEN : And UCB Submit Biologics License Application For Romosozumab To The FDA
07/22 AMGEN : UCB and Amgen submit FDA application for Osteoporosis drug
07/21 AMGEN : Patent Issued for Method for Culturing Mammalian Cells to Improve Recomb..
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21 AMGEN : Announces Settlement Of Securities Litigation
07/20 AMGEN : Technical Coverage on Biotechnology Equities -- Galena Biopharma, Eleven..
07/20 AMGEN : Assigned Patent
More news
Sector news : Bio Therapeutic Drugs
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08 Medtech's 2016 stock surge confronts second-quarter test
07/07DJJuno Shares Plunge as Drug Trial Placed on Hold After Patient Deaths
07/06DJBiotech Medivation Opens Door to Takeover Talks -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:36p MY EARNINGS GAME PLAN : July 25-27
12:05p TOP 10 HEALTH CARE STOCKS : Which To Buy? Part 3
07/23 Biogen Q2 Plusses And Minuses
07/22 6 MONTH PORTFOLIO UPDATE : Good News, Double-Digit Increase In Both Income And V..
07/22 Amgen declares $1.00 dividend
Advertisement
Financials ($)
Sales 2016 22 569 M
EBIT 2016 10 789 M
Net income 2016 7 447 M
Debt 2016 2 908 M
Yield 2016 2,41%
P/E ratio 2016 16,88
P/E ratio 2017 15,39
EV / Sales 2016 5,64x
EV / Sales 2017 5,29x
Capitalization 124 454 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 185 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Madhavan Balachandran Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
CELGENE CORPORATION-10.22%83 285
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
ACTELION LTD22.85%19 820
More Results